Recursion Pharmaceuticals, Inc. (RXRX) Guidance & Earnings Results
On 2026-08-05 Recursion Pharmaceuticals, Inc. lowered guidance: "FY26 cash operating expense guidance reduced to <$375M from…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RXRXRecursion Pharmaceuticals, Inc.Follow RXRX — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Lowered | FY26 cash operating expense guidance reduced to <$375M from <$390M · full year |
Recursion Pharmaceuticals, Inc. — questions
- What guidance did Recursion Pharmaceuticals, Inc. give?
- On 2026-08-05: "FY26 cash operating expense guidance reduced to <$375M from <$390M"
- When does Recursion Pharmaceuticals, Inc. report earnings?
- Recursion Pharmaceuticals, Inc.'s next earnings report is expected on 2026-11-11.
Every figure on this page comes from Recursion Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.